Pharmaceuticals

Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Size Forecast: Revenue and CAGR by 2029

November 10, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Global Market Value Of The Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Industry In 2025?

The warm autoimmune hemolytic anemia (waiha) treatment market size has experienced strong growth in recent years. It is forecast to increase from $0.55 billion in 2024 to $0.6 billion in 2025, achieving a compound annual growth rate (CAGR) of 8.7%. This historic period’s growth can be ascribed to an increase in healthcare expenditure, a rise in clinical trials focusing on rare hematologic diseases, the expansion of patient support and advocacy networks, and an aging population.

The warm autoimmune hemolytic anemia (waiha) treatment market is projected to experience robust expansion over the coming years, reaching a valuation of $0.85 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 9.2%. This anticipated growth during the forecast period is primarily driven by the escalating incidence of autoimmune disorders, enhanced awareness among healthcare professionals, increased acceptance of biologics and targeted therapies, and the expanding utilization of off-label medications for autoimmune conditions. Key developments anticipated in this period encompass innovations in monoclonal antibody treatments, the incorporation of next-generation sequencing (NGS) into diagnostic procedures, progress in immunology research, and the emergence of technology-facilitated drug discovery platforms.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24426&type=smp

Which Drivers Are Shaping The Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Industry’s Market Share?

Rising healthcare spending is anticipated to propel the expansion of the warm autoimmune hemolytic anemia (WAIHA) treatment market. This expenditure represents the aggregate resources devoted to health services, covering prevention, diagnosis, treatment, and disease management by individuals, governments, and various organizations. Medical technology advancements contribute to increased healthcare costs, given that novel diagnostic tools and therapies frequently entail substantial expenses for their development, deployment, and continuous patient support. Crucially, healthcare expenditure facilitates warm autoimmune hemolytic anemia (WAIHA) treatment through funding research, enabling access to sophisticated diagnostic instruments, and securing specialized therapies essential for disease management and control. For example, data from May 2024 by the UK’s Office for National Statistics indicated a 2.8% real-term rise in long-term health and social care expenditures in 2022, with total healthcare spending seeing a 5.6% increase in 2023. Consequently, the escalation in healthcare expenditure is a primary driver for the growth of the warm autoimmune hemolytic anemia (WAIHA) treatment market.

What Are The Key Segments In The Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market?

The warm autoimmune hemolytic anemia (waiha) treatment market covered in this report is segmented –

1) By Treatment Type: Corticosteroids, Monoclonal Antibodies, Intravenous Immunoglobulin (IVIG), Blood Transfusions, Splenectomy

2) By Route Of Administration: Oral, Intravenous, Subcutaneous

3) By Patient Demographics: Children, Adults, Geriatric

4) By Therapeutic Area: Primary Autoimmune Disorders, Secondary Autoimmune Disorders, Genetic Predisposition

5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Corticosteroids: Prednisone, Dexamethasone, Methylprednisolone

2) By Monoclonal Antibodies: Rituximab, Sutimlimab, Bortezomib

3) By Intravenous Immunoglobulin: Standard IVIG, High-Dose IVIG Therapy, Pooled Plasma-Derived Immunoglobulins

4) By Blood Transfusions: Leukoreduced RBC Transfusions, Emergency Transfusions, Phenotypically Matched RBC Transfusions

5) By Splenectomy: Laparoscopic Splenectomy, Prophylactic Treatments Post-Splenectomy, Open Splenectomy

What Are The Latest Industry Trends Transforming The Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market?

Major companies operating in the warm autoimmune hemolytic anemia (WAIHA) treatment market are focusing on developing innovative solutions, such as monoclonal antibodies, to address unmet clinical needs and improve patient outcomes. Monoclonal antibodies are lab-engineered proteins designed to target specific immune cells or pathways, thereby reducing the destruction of red blood cells in warm autoimmune hemolytic anemia. For instance, in July 2023, IASO Biotechnology, a China-based biopharmaceutical company, announced the U.S. Food and Drug Administration (FDA) approval for IASO-782 Injection for use in clinical studies for autoimmune hematological conditions in the United States, including warm autoimmune hemolytic anemia (WAIHA) and primary immune thrombocytopenia (ITP). Targeting CD19, this fully human monoclonal antibody features Fc mutations to increase ADCC activity while maintaining other Fc functions. It selectively depletes CD19+ B cells, plasma blasts, and some plasma cells, which are responsible for producing auto-reactive antibodies. Due to its distinct mechanism, IASO-782 may be used to treat autoimmune illnesses caused by pathogenic B and plasma cells, such as ITP and AIHA.

Which Leading Players Are Enhancing Their Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Presence Worldwide?

Major companies operating in the warm autoimmune hemolytic anemia (WAIHA) treatment market are Johnson & Johnson, F. Hoffmann-La Roche Ltd., Sanofi S.A., AstraZeneca Plc, Novartis AG, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Agios Pharmaceuticals Inc., Incyte corporation, Mallinckrodt Pharmaceuticals, Hutchison Medipharma Limited, BioCryst Pharmaceuticals Inc., Xencor Inc., Annexon Inc., Rigel Pharmaceuticals Inc., Apellis Pharmaceuticals Inc., Momenta Pharmaceuticals Inc., Immunovant Inc., Zenas BioPharma Inc., Alexion Pharmaceuticals Inc., Mitsubishi Tanabe Pharma Corporation.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/warm-autoimmune-hemolytic-anemia-waiha-treatment-global-market-report

Which Region Currently Holds The Largest Share Of The Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market?

North America was the largest region in the warm autoimmune hemolytic anemia (WAIHA) treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the warm autoimmune hemolytic anemia (WAIHA) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Report:

https://www.thebusinessresearchcompany.com/customise?id=24426&type=smp

Browse Through More Reports Similar to the Global Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market 2025, By The Business Research Company

Autoimmune Disease Diagnosis Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/autoimmune-disease-diagnosis-global-market-report

Granulocyte Colony Stimulating Factors Market 2025

https://www.thebusinessresearchcompany.com/report/granulocyte-colony-stimulating-factors-market

Drug Delivery Devices Market 2025

https://www.thebusinessresearchcompany.com/report/drug-delivery-devices-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info